Recludix Pharma named Matthew Caldemeyer as chief business officer Thursday morning.
Caldemeyer most recently served as VP of business development at Everest Medicines, a Shanghai-based biotech, where he managed an alliance with Gilead Sciences.
Prior to that, he worked at a number of pharmaceutical companies, including mbrx, Array Biopharma, Amgen and Eli Lilly and Company.
“Matt has broad experience across business development, corporate strategy and finance,” Recludix CEO Nancy Whiting, Pharm.D, said in a statement. “His established track record of productive business development transactions and successful alliance management will contribute to our goal of delivering important new therapies to patients.”